John Hood

1.9K posts

John Hood

John Hood

@PrezCamacho

CEO, Cofounder, Chairman of Endeavor Biomedicines

San Diego, CA Katılım Mart 2009
1.2K Takip Edilen625 Takipçiler
John Hood
John Hood@PrezCamacho·
@TexAgs Huge fan of Coach Sampson. Second favorite coach in tourney behind Bucky. He is being too nice to Buzz.
English
0
1
10
424
TexAgs
TexAgs@TexAgs·
Houston head coach Kelvin Sampson on Bucky McMillan: "My dad was a high school coach for 30 plus years, so I've always had an affinity for high school coaches. Bucky was a great hire by A&M. He's unique. He fits. I thought Buzz was great for A&M, and I think Bucky will be too."
English
6
8
548
28.1K
John Hood retweetledi
Rep. Mike Levin
Rep. Mike Levin@RepMikeLevin·
A three-year-old company operating out of a WeWork with reportedly fewer than five employees is being considered for up to $25 BILLION in nuclear energy funds from a trade deal Trump brokered with Japan. The company has never built a nuclear plant or completed a nuclear project of any kind. What does this company bring to the table? The father of its CEO donated $2 million+ to Trump and the GOP, and one of its advisors is a former RNC co-chair and Trump appointee. In this Administration, that’s apparently all you need.
English
440
8.6K
15.3K
563.2K
John Hood retweetledi
Dr. Toonces, MD, PhD
Dr. Toonces, MD, PhD@toonces4280·
Two weeks ago I watched the FDA call the only promising Huntington's disease therapy "snake oil" on an anonymous press call. The official who said it is gone. A US senator launched an investigation. The stock went from $9 to $21. But the drug still isn't approved. And this problem is way bigger than one therapy. Huntington's disease is 100% fatal. Zero approved treatments slow it. AMT-130 showed 75% slowing of progression with a p-value of .003. The FDA's response? Reverse their own written agreement and demand a new trial where dying patients undergo brain surgery and receive nothing. 48,000 families fought back. It worked. But we can't run that playbook for every drug, for every disease, for every family. A guy in Australia used AI to design a personalized cancer vaccine for his dying dog. It worked. He said the red tape took longer than designing the vaccine itself. Three months of paperwork, two hours every night, for a 100-page ethics document. For his own dog. Sid Sijbrandij, the co-founder of GitLab, was told he had no options left for his osteosarcoma. He went into "founder mode on his cancer." Self-funded experimental therapies. Assembled an entire team to navigate the regulatory maze. He's been relapse-free since 2025. He's also a billionaire. Most patients aren't. Jake Seliger had advanced throat cancer. He was just as willing to try anything. He couldn't hire a team to navigate the system. He died. Same disease. Same willingness. Different bank accounts. Different outcomes. The system we built to protect patients has become the system that kills them. It takes 7 to 10 years and $1.2 billion to move a promising idea to Phase III results. Some of that delay is science. A lot of it is paperwork. Australia runs clinical trials 2.5 to 3 times cheaper and faster than the US. No increase in safety events. Three decades of data proving it works. US biotechs are moving their early trials there because it's easier to test drugs in Australia than in America. That should embarrass everyone in Washington. The real fix isn't just personnel changes at the FDA. It's structural. Let researchers choose their ethics review board. Create a notification pathway for early trials instead of requiring pre-approval for everything. Scale manufacturing requirements to match trial size, not commercial production. A terminal patient willing to accept risk should not need a billionaire's resources to access an experimental therapy. A therapy that met its primary endpoint should not be called "snake oil" by an anonymous government official. A family watching someone die should not be told the paperwork isn't done yet. The Huntington's fight isn't over. The Q2 FDA meeting and 48-month data are next. But if this moment only fixes one drug for one disease, we've wasted it. The system needs to change. Not just the people running it. Read @RuxandraTeslo's piece on what real reform looks like. Link in the replies. $QURE #HuntingtonsDisease #AMT130 #RareDisease #RightToTry
English
6
29
112
7.9K
John Hood retweetledi
T𑀣ᑏI 🇦🇱🇺🇸
T𑀣ᑏI 🇦🇱🇺🇸@RexKwonDo92·
The price of Spice rises by 10%, as intergalactic Guild shipping lanes are blocked by Fremen forces in response to the Harkonnens illegal attack on Arrakis. Arrakis, 10, 191AG, colorized
T𑀣ᑏI 🇦🇱🇺🇸 tweet media
English
135
1.9K
17.5K
487.6K
John Hood
John Hood@PrezCamacho·
@Dr_R_Kurzrock Seems like perfect case for accelerated approval coupled to requirement for confirmatory study. For fatal diseases with no effective therapy a regulator has to realize that doing nothing does maximal harm.
English
1
0
7
169
Razelle Kurzrock, MD
Razelle Kurzrock, MD@Dr_R_Kurzrock·
For fatal disease, Is it worse to approve agent with a possibility of it turning out to be ineffective because trial was imperfect, or is it worse to delay possibly effective agent waiting for perfect trial that requires forcing desperate pts to undergo sham brain placebo surgery
LabRadar ✡️@LabbRadar

$QURE It requires forcing desperate patients with a 100 percent fatal genetic disease to undergo invasive brain surgery solely to inject a placebo, while withholding a therapy that has demonstrated 36 months of profound disease slowing.

English
5
4
23
4.3K
John Hood
John Hood@PrezCamacho·
@MaartenDik US patients should not be denied access to drugs approved in Europe and UK. There should be reciprocity between US and EMA regulators so US patients have access to these therapies. The US bureaucracy should not be more obstructionist than EU, but they are.
English
0
0
0
15
Maarten 🇪🇺
Maarten 🇪🇺@MaartenDik·
Holy moly! This is specifically about Sydnexis, but think about all the other recent events with $QURE etc. Also, the EMA and MHRA DID approve that same drug. A little snippet: “Sydnexis invited Robert Clark, a renowned pediatric ophthalmologist, to accompany its executives to a meeting with FDA staff last month to address the agency’s criticism. It was clear the FDA reviewers “did not understand the disease at all,” Dr. Clark tells us. A staff statistician at the meeting claimed the eye drops’ benefits diminished over time, but this was incorrect.”
Maarten 🇪🇺 tweet mediaMaarten 🇪🇺 tweet media
English
5
1
37
1.8K
John Hood
John Hood@PrezCamacho·
@SynBio1 Welcome to our hell says every pharma/biotech developer ever.
English
0
0
2
166
John Hood retweetledi
CP2
CP2@LuckyPenguin10·
Here's the issue with Vinay Prasad (and FDA Commissioner, Marty Makary): I don't doubt that Prasad's intensions were pure. I don't know him. But his approach was a maximalist framework that put ideology over pragmatism. The result of that was throwing out the baby with the bathwater on several critical decisions. When those decisions involve therapies for life threatening diseases, that kind of rigidity becomes dangerous. Especially so in the case of rare and ultra rare diseases. By many credible sources, Prasad ran CBER like a dictatorship. Enormous decisions affecting millions were concentrated in the judgment of one individual, often in areas far outside his clinical expertise. This came to a head with $QURE AMT-130. Whether it was Makary's "burr hole" comments, Prasad's "nicks in the scalp" comment, or the many other examples... it became *abundantly* clear that they were weighing in on neurosurgical and neurological issues without real domain expertise. Now let's be direct about what that signals... That behavior reflects a level of intellectual hubris where ego dominates every other variable in the decision making process. To be clear (it's worth repeating myself): I don't believe Prasad or Makary are evil people. In fact, I actually believe they think they are doing the right thing. But medicine is full of brilliant specialists who understand that expertise does not automatically transfer across fields. Being world class in, let's say, oncology or gastrointestinal surgery does not make you an authority on complex neurological therapies. Most medical professionals, who possess an ounce of humility, understand this. So what should a regulator at the @US_FDA do in that situation? The answer is simple. In fact, it’s so simple, that the decision to not do this speaks volumes about where your intentions and motivations lay. The answer? SPEAK WITH THE CLINICIANS CLOSEST TO THE DATA  AND THE PATIENTS. (Sorry for shouting.) > Leverage their experience. > Engage the researchers running the trials. > Debate the evidence with the folks on the field. > Collaborate with them on a thoughtful path forward. AMT-130 trial's lead scientific advisor is Dr. Sarah Tabrizi, one of the world's leading Huntington's clinicians and researchers. Beyond being one of *the* subject matter experts specifically focused on Huntington's, Dr. Tabrizi is widely regarded as one of the most high-integrity practitioners in the field. (Maybe also pay attention to the ~48,000 people across two petitions asking the FDA to listen.) What you don't do is predetermine that any therapy or program that doesn't fit the rigid boundaries of your ideology is dead on arrival. That’s what Vinay Prasad did. And that’s what Marty Makary supported. How can you call that an evidence based regulatory framework? That's an operating principle driven by ideology. How can an FDA that operates that way claim to put patients first? They can't. @SenGillibrand @SenRickScott @SenRonJohnson @RepAuchincloss
Anish Koka, MD@anish_koka

Great non technical essay on the roots of Vinay’s exit : patients with terrible diseases desperate for hope. Even better : Maps a way forward from this debacle that doesn’t involve burning everything down.

English
10
10
54
8.7K
John Hood retweetledi
Frankie G
Frankie G@IamnotDescartes·
To be clear: The FDA is approving a drug that doctors from autism advocacy groups say are ineffective. By contrast, HD advocates and some neuroscientists argue that the long-term data for AMT-130 appear robust. Yet the head of CBER has dismissed it as "snake oil." $QURE
Pearl Freier@PearlF

On the new FDA approval today for leucovorin at HHS Secretary Kennedy's request $IBB $BBC $XBI, “There is no evidence to say that leucovorin will help most people with autism, there’s certainly no evidence to say it’s safe,” said Dr. Alycia Halladay of the Autism Science Foundation, in an interview.

English
0
6
51
6.8K
John Hood retweetledi
Mike Convente
Mike Convente@mikeconvente·
LOL, the FDA is ok with external control data when it's an indication RFK Jr et al are hyper-fixated on, but not for universally fatal neurodegenerative diseases... $GSK $QURE $XBI endpoints.news/fda-widens-use…
English
4
8
65
11.2K
Matthew Herper
Matthew Herper@matthewherper·
@AAMortazavi @AppleHelix @venkmurthy I think he's prone to motivated reasoning that he doesn't recognize. In Kahneman’s terms, he mostly uses system 1. He knows a lot but that's not really the issue.
English
6
0
16
958
John Hood retweetledi
Dustin
Dustin@r0ck3t23·
Jeff Bezos just identified the most expensive bureaucratic failure in the American economy. It fits in one sentence. Bezos: “Why does it take months and months and months to get a building permit? It doesn’t make any sense.” It doesn’t make any sense because a building code is not a judgment call. It is an algorithm. And algorithms should be executed by machines. Bezos: “Miami should have an AI application that reads your building permit for a new house or a new building and it should give you a yes or a no in ten seconds.” Ten seconds. Not three months. Not six weeks. Not whenever the reviewer clears their backlog. Bezos: “If the answer is no, it should tell you the six things you have to change to get a yes.” No ambiguity. No interpretation. No bureaucratic delay dressed up as due diligence. Just a deterministic feedback loop compressing months of institutional friction into a single automated decision. We are competing against sovereign adversaries deploying gigawatt data centers and scaling physical infrastructure at a pace that does not stop to ask permission. And we are losing ground to countries that never needed to. The AI arms race is not only fought in data centers. It is fought in the gap between when someone decides to build something and when the government allows it. Every month this system runs on biological speed is a month that cannot be recovered. The governments that integrate AI into their core civic functions will trigger a wave of physical development the old world could never produce. The ones that refuse will still be reviewing the same forms a decade from now. While the cities that said yes are already living inside the future they built. The bottleneck was never ambition. It was always the man holding the rubber stamp deciding when ambition was allowed to begin. And the stamp is just a rubber version of the algorithm that should have been running this whole time.
English
282
690
3.4K
291.9K
John Hood retweetledi
Alex
Alex@acesobiologics·
@AppleHelix @anish_koka Will say it until I'm blue in the face but FDA needs approval routes similar to the EU's Conditional Marketing Authorisation and Exceptional Circumstances. CMA could be ideal in uniQure's situation, where you have annual re-review and significant PASS/PAES to convert to full MA.
English
0
2
6
2.8K
John Hood retweetledi
Dr. Toonces, MD, PhD
Dr. Toonces, MD, PhD@toonces4280·
This is an HHS spokesperson telling a concerned citizen to “read up on your history” and asking if they’re “too old and forget.” Huntington’s disease destroys memory, cognition, and motor function. Patients lose the ability to speak, think, and recognize their families. This is who the FDA sends to speak for them. $QURE #HuntingtonsDisease
Andrew Nixon@AndrewNixonHHS

@mike98572986 The company already conducted a sham trial of what we are asking. Why don’t you read up on your history? Or maybe you’re too old and forget.

English
6
13
80
10.6K
John Hood
John Hood@PrezCamacho·
@IamnotDescartes @WSJ FDA is much more capricious, erratic and challenging to work with than EMA or MHRA
English
0
0
1
56
Frankie G
Frankie G@IamnotDescartes·
@WSJ The worst part is that the FDA is gaslighting us, with Makary saying he wants U.S. biotech to beat China. My brother in Christ, you’re not even going to beat Europe with the way you’re running things. The lives of patients with rare diseases are not a game put your ego aside ffs.
English
1
1
15
348
John Hood retweetledi
Jing Liang 🇺🇦
Jing Liang 🇺🇦@AppleHelix·
According to Chatgpt, no FDA approved gene therapy required sham control in the pivotal study.
Jing Liang 🇺🇦 tweet media
Lauren Holder@laurencurehd

As a person with Huntington’s disease who would also be eligible for the clinical trial and has been provided the actual details from the sponsor, here is my response as to why this "sham" surgery is unethical: Okay, so - when participating in a clinical trial with a placebo arm to it to act as a control, a pill vs a "sham" surgery is very different. Even our clinical trials where the drug is delivered via spinal tap is different because they aren't gene therapies; they are gene-modifying drugs that leave your system and you can have a "washout period", which means the drug is completely gone. The benefit of this (especially in rare diseases) is that people are able to participate in future research since the drug can actually "washout". It's still considered unethical in HD, though, to expect that someone receive a placebo (sugar pill instead of actual drug) and be "blinded" (not knowing if you received the real thing or not) for too long, because a lot of times, these treatments work better the earlier you are in the disease. If you "blind" people for too long, they then may not be eligible not only for the real drug in an open-label extension, but they could also be excluded from other clinical trials because they've progressed too much to meet the clinical trial criteria, which is very strict. So the issues with the "sham surgery" placebo arm are: 1- This is a one-and-done gene therapy. There are not multiple treatments. The first people in the AMT-130 trial have been followed for 4+ YEARS and counting. It doesn't wash out ever. Because of that, people who participate in this clinical trial will never be able to participate in future research. Imagine doing that to someone and making them have a "sham" surgery, disqualifying them from future research and not giving them a chance for a treatment at all. 2 - why couldn't they just do the real surgery after the sham and give them the real thing? Great question! That was actually tried, but they found that the people who did sham progressed during the trial to a point they were no longer eligible for it. So very few were able to actually do that, which is the one of the reasons the FDA agreed in December 2024 that UniQure could instead use natural history data instead of doing the "sham" procedure. It's unethical in a rare, fatal neurodegenerative disease. This decision WAS ALREADY MADE BY THE FDA in 2024. 3 - The real surgery to receive the real drug involves going under anesthesia for up to 15 hours, having burr holes drilled (very common, standard procedure already done every day for other things, but still a hole in the head that requires anesthesia and a surgical room), delivering the drug right to the part of the brain affected by HD that this drug targets. After surgery, the participant then has to recover in the hospital and be monitored for several days inpatient before they are allowed to go home. They will follow up regularly for the next 5+ years to see how they are doing, if they are progressing, how much they are progressing, etc. Now - imagine going through ALL of that still - the only difference is that instead of delivering the drug into your brain, they stop after making the incisions where the burr holes would be, let you stay under anesthesia for the same amount of time and everything, put sutures at the incisions and that's it. They don't tell you whether you received the treatment. You still have to go through recovery and monitoring just like the real thing. It is absolutely evil to do that to someone with HD. It has already been proven and accepted that they will progress faster because the data shows after almost 4 years of monitoring that it slows progression of the disease by 75%. So to ask NOW, at this point, when we already know this, to ask people with HD to undergo a "sham" surgery is not just unethical, it's evil. It's disgusting.

English
11
19
105
18.6K
John Hood retweetledi
Peter Mantas
Peter Mantas@peter_mantas·
Here’s why RCT feasibility varies across neurodegenerative diseases treated with gene therapy and cell therapy (for HD/Parkinson’s/Epilepsy). 1. Epilepsy (the most feasible): Seizures are frequent, countable events making endpoints clear and trials shorter. Patients can remain on existing medications during the trial. Crucially, the disease isn’t uniformly fatal so the ethical barrier to sham surgery is dramatically lower. IRBs approve it, patients consent, procedures are shorter and neurosurgeons perform it. This is why Neurona and amt-260 WILL have RCTs. 2. Parkinson’s (feasible esp for cell therapy but harder): No closing eligibility window because a patient eligible today REMAINS eligible in three years. Longer disease course gives time to run proper trials. Established symptomatic treatments mean placebo patients aren’t being denied their only hope. Natural history variability makes external controls harder to validate but sham surgery ethics are manageable in a non-fatal disease. Quick to see improvements in motor skills and scores. 3. Huntington’s (essentially infeasible): Progression is slow making trials long and expensive. The results are not quick like Parkinson’s motor scores. The TFC 9-13 surgical eligibility window closes permanently (aka you’re toast). Patients enrolled at TFC 11 progress out of the eligible population before the trial completes. Natural history is so uniform that external controls are actually more scientifically valid here than in ANY other indication. Withholding treatment via sham brain surgery in a uniformly fatal disease with no alternatives is ethically indefensible. IRBs won’t approve it at scale, neurosurgeons won’t perform it and patients won’t consent.
English
1
11
85
26.4K